Dulaglutide OK for Primary and Secondary CV Risk Reduction in US Dulaglutide OK for Primary and Secondary CV Risk Reduction in US

Dulaglutide is the first and only type 2 diabetes medicine approved to reduce CV events in adults with, and without, established CVD.FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news